Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

Inclusion Criteria: 1. Male or female, Age 18-75 years old; 2. Patients with pathologically/histologically confirmed diagnosis of solid tumors (such as advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma) have received at least once systemic standard treatment and disease progressed; or refused/ cannot tolerate the subsequential standard treatment after the first line treatment; 3. Must have CLDN18.2-positive tumor expression ≥10% as determined by the CLDN18.2 IHC assay; 4. Estimated life expectancy \> 3 months (according to investigator's judgement); 5. At least 1 measurable lesion per RECIST 1.1; 6. The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 7. Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis; 8. Patients should have reasonable CBC counts, renal and hepatic functions; 9. No other serious diseases (autoimmune diseases or any immune deficiency disease); 10. Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception for at least 12-months after T-cell infusion; 11. Men must be willing to use effective and reliable method of contraception and are not allowed to donate sperm for at least 12-months after T-cell infusion; 12. Voluntarily participate in the research, understand and sign the informed consent. Exclusion Criteria: 1. Pregnant or lactating women; 2. Patient with hepatitis B or C active period, HIV infection ≥ the upper limit of the normal level; 3. Any uncontrolled active infection; 4. Patients who have clinically significant thyroid dysfunction; 5. Patients who have received prior cellular therapy such as CAR T, TCR, tumor-infiltrating lymphocytes; 6. Patients who are allergic to immunotherapy or any associated drugs, such as cytokines and the preconditioning regimen (cyclophosphamide, fludarabine); 7. Patients with untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression; 8. Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients; 9. Unstable pulmonary embolism, deep venous embolism or other major arterial/venous thromboembolic events occurred within 6 months before enrollment; 10. Patients with active autoimmune diseases, history of autoimmune diseases or other diseases in need of immunosuppressive therapy; 11. Patients with major surgery or injury less than 4 weeks prior to leukapheresis or plan to have major surgery during the research period; 12. Patients with second malignancies in addition to targeted malignancies within 5 years before screening; 13. Patients with unstable/active ulcer or digestive tract bleeding; 14. Patient suffering from diseases that affect the signing of written informed consent or compliance with research procedures; or are unwilling or unable to comply with research requirements; 15. Patients who have a history or a tendency for digestive tract bleeding; 16. Patients who are inappropriate to participate in this research as considered by PI.